These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8202971)

  • 1. Ganglioside GM1 in acute ischemic stroke. The SASS Trial.
    Stroke; 1994 Jun; 25(6):1141-8. PubMed ID: 8202971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating neuroprotective agents for clinical anti-ischemic benefit using neurological and neuropsychological changes after cardiac surgery under cardiopulmonary bypass. Methodological strategies and results of a double-blind, placebo-controlled trial of GM1 ganglioside.
    Grieco G; d'Hollosy M; Culliford AT; Jonas S
    Stroke; 1996 May; 27(5):858-74. PubMed ID: 8623106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study.
    Schneider JS; Roeltgen DP; Mancall EL; Chapas-Crilly J; Rothblat DS; Tatarian GT
    Neurology; 1998 Jun; 50(6):1630-6. PubMed ID: 9633704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GM1 ganglioside for acute ischemic stroke. Trial design issues.
    Alter M
    Ann N Y Acad Sci; 1998 Jun; 845():391-401. PubMed ID: 9668372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the Early Stroke Trial.
    Lenzi GL; Grigoletto F; Gent M; Roberts RS; Walker MD; Easton JD; Carolei A; Dorsey FC; Rocca WA; Bruno R
    Stroke; 1994 Aug; 25(8):1552-8. PubMed ID: 8042206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GM1 ganglioside in the treatment of Parkinson's disease.
    Schneider JS
    Ann N Y Acad Sci; 1998 Jun; 845():363-73. PubMed ID: 9668369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group.
    De Deyn PP; Reuck JD; Deberdt W; Vlietinck R; Orgogozo JM
    Stroke; 1997 Dec; 28(12):2347-52. PubMed ID: 9412612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GM1 ganglioside therapy in acute ischemic stroke. Italian Acute Stroke Study--Hemodilution + Drug.
    Argentino C; Sacchetti ML; Toni D; Savoini G; D'Arcangelo E; Erminio F; Federico F; Milone FF; Gallai V; Gambi D
    Stroke; 1989 Sep; 20(9):1143-9. PubMed ID: 2672425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GM1 ganglioside therapy in acute ischemic stroke.
    Oppenheimer S
    Stroke; 1990 May; 21(5):825. PubMed ID: 2339464
    [No Abstract]   [Full Text] [Related]  

  • 10. GM1 ganglioside in Parkinson's disease: Results of a five year open study.
    Schneider JS; Sendek S; Daskalakis C; Cambi F
    J Neurol Sci; 2010 May; 292(1-2):45-51. PubMed ID: 20206941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Lubeluzole International Study Group.
    Diener HC; Hacke W; Hennerici M; Rådberg J; Hantson L; De Keyser J
    Stroke; 1996 Jan; 27(1):76-81. PubMed ID: 8553408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group.
    Clark WM; Warach SJ; Pettigrew LC; Gammans RE; Sabounjian LA
    Neurology; 1997 Sep; 49(3):671-8. PubMed ID: 9305321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group.
    Yamaguchi T; Sano K; Takakura K; Saito I; Shinohara Y; Asano T; Yasuhara H
    Stroke; 1998 Jan; 29(1):12-7. PubMed ID: 9445321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is ganglioside GM1 effective in the treatment of stroke?
    Braune S
    Drugs Aging; 1991 Jan; 1(1):57-66. PubMed ID: 1794005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy.
    Schneider JS; Roeltgen DP; Rothblat DS; Chapas-Crilly J; Seraydarian L; Rao J
    Neurology; 1995 Jun; 45(6):1149-54. PubMed ID: 7783880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of Ganglioside GM1 in Ischemic Stroke: Ganglioside GM1: A Critical Review.
    Zhang W; Krafft PR; Wang T; Zhang JH; Li L; Tang J
    Cell Transplant; 2019 Jun; 28(6):657-661. PubMed ID: 30666888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial of ganglioside GM1 in acute stroke.
    Hoffbrand BI; Bingley PJ; Oppenheimer SM; Sheldon CD
    J Neurol Neurosurg Psychiatry; 1988 Sep; 51(9):1213-4. PubMed ID: 3066849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of GM1 ganglioside in cerebrovascular diseases: a double-blind trial in 40 cases.
    Battistin L; Cesari A; Galligioni F; Marin G; Massarotti M; Paccagnella D; Pellegrini A; Testa G; Tonin P
    Eur Neurol; 1985; 24(5):343-51. PubMed ID: 3902480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Trials of monosialoganglioside (Sygen) treatment in ischemic stroke].
    Wender M; Mularek J; Godlewski A; Losy J; Michałowska-Wender G; Sniatała-Kamasa M; Wójcicka M
    Neurol Neurochir Pol; 1993; 27(1):31-8. PubMed ID: 8502357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.